Effects of CRT Optimization as Assessed by Cardiac MR
Heart Failure, Systolic
About this trial
This is an interventional treatment trial for Heart Failure, Systolic focused on measuring Cardiac Resynchronization Therapy, Pacing, Electrocardiography, Cardiac Magnetic Resonance Imaging, Echocardiography, Optimization of Cardiac Devices, Heart Failure
Eligibility Criteria
Inclusion Criteria:
- Currently on standard medical therapy
- CRT device in place for > 4 months
- Non-responder (ejection fraction improvement with CRT < 5%) or incomplete responder (ejection fraction < 40%)
- Suboptimal electrical wavefront fusion at current CRT programming as observed on 12-lead ECG
- Left bundle branch block, interventricular conduction delay or right ventricular paced underlying QRS complex
- Age > 18 years
Exclusion Criteria:
- Decompensated heart failure
- Right bundle branch block
- Pregnancy or lactation
- History of severe allergic reactions to ECG gels, electrode adhesives, and/or cardiac magnetic resonance contrast (e.g. gadolinium)
- Implantation of pacing lead in the his bundle or left bundle branch
- Frequent ventricular ectopy as defined as >10% premature ventricular contraction burden by either device interrogation or Holter monitor, or sustained ventricular tachycardia/ventricular fibrillation
- Uncontrolled atrial fibrillation (HR > 100 bpm)
- Patient is enrolled in concurrent research study that would potentially confound the results of this study (noting: co-enrollment acceptable if patient is enrolled in registry study)
Sites / Locations
- Minneapolis Heart Institute - Abbott Northwestern Hospital (MHI West)Recruiting
- United Heart & Vascular Clinic - Nasseff Specialty Center (MHI East)Recruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Baseline CRT programming
Electrocardiography-guided optimal CRT programming
The comparator arm patients will remain at baseline CRT programming for the first 6 months, and then will crossover to the experimental arm and CRT device will be programmed to optimal settings derived from the electrocardiographic assessment for the following 6 months.
The experimental arm patients will have CRT device programmed based on the electrocardiographic assessment for 12 months.